Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Klaviyo Q3 Non-GAAP Earnings, Revenue Rise

Klaviyo Q3 Non-GAAP Earnings, Revenue Rise

MT newswireMT newswire2026/11/04 21:57
05:57 PM EST, 11/04/2026 (MT Newswires) -- Klaviyo (KVYO) reported Q3 non-GAAP earnings late Wednesday of $0.22 per diluted share, up from $0.18 a year earlier. Analysts polled by FactSet expected $0.17. Revenue for the quarter ended Sept. 30 was $387.2 million, up from $310.9 million a year earlier. Analysts expected revenue of $380.0 million. The company expects Q4 revenue of $421 million to $425 million. Analysts expect revenue of $422.7 million. It also raised its full-year 2026 revenue guidance to $1.537 billion to $1.541 billion, from $1.526 billion to $1.534 billion earlier. Analysts expect revenue of $1.53 billion.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss